Endocytosis and recycling control the uptake and retrieval of various materials in eukaryotic cells. Mammalian cells have ...

Medications for bladder control include anticholinergics, Botox, topical estrogen, and more. Learn more about the available prescription and over-the-counter options for managing incontinence.

Previous studies have identified the adrenergic receptor (AR)-binding potential of PAGln, which suggests its potential role in allosteric modulation. ARs are host receptors involved in a wide ...

Neffy is a small molecule commercialized by ARS Pharmaceuticals, with a leading Pre-Registration program in Anaphylaxis.

Objective: To compare the haemodynamic effects of nebivolol, a highly selective antagonist of 1-adrenergic receptors with additional actions caused via the L-arginine/nitric oxide pathway ...

The initial treatment is with alpha-adrenergic receptor blockers, medication that can bring relief within days. In your longer letter you say you were treated with one such drug – tamsulosin – but it ...

Third-generation α 1-adrenergic antagonists are pharmacologically uroselective in that they are competitive antagonists for prostatic α 1A-receptors. [16,17] Blockade of these receptors relaxes ...

USF faculty continually demonstrate their skills in conducting high-impact research and innovation to advance frontiers of ...

Study identifies phenylacetylglutamine (PAGln), a gut microbiome metabolite, as a novel allosteric modulator of β2-adrenergic receptors, offering insights into its role in cardiovascular disease ...

Dr. Neil Marwah began his career by founding Desert Kidney Associates (DKA), a nephrology practice that set a new standard for care in Arizona. As a patient-first organization, he built DKA up to 20 ...

The beta-adrenergic blockade did not alter these ... other sympathomimetic drugs could be accounted for if two sets of receptors, alpha and beta, were present in or near muscles and glands ...

Top-line data from VEGA-3 Phase 3 trial expected in first half of 2025Top-line data from LYNX-2 Phase 3 trial in patients with decreased visual ...